Arcus Biosciences Inc

For the period ended Jun 30, 2024. Filed Aug 8, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 8, 2024

RCUS$18.67-1.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(In millions, except per share amounts)

	Three Months EndedJune 30,		Six Months EndedJune 30,
	2024	2023	2024	2023
Revenues:
License and development services revenue (Includes $25, $19, $156 and $36 from a related party)	$28	$19	$163	$36
Other collaboration revenue (Includes $11, $10, $21 and $18 from a related party)	11	10	21	18
Total revenues	39	29	184	54
Operating expenses:
Research and development (Includes $14, $34, $30 and $67 of net recoveries from a related party)	115	84	224	165
General and administrative	30	28	62	58
Impairment of long-lived assets (see Note 11, Leases)	—	—	20	—
Total operating expenses	145	112	306	223
Loss from operations	(106)	(83)	(122)	(169)
Non-operating income (expense):
Interest and other income, net	13	9	26	18
Effective interest on liability for sale of future royalties	—	—	(1)	(1)
Total non-operating income, net	13	9	25	17
Loss before income taxes	(93)	(74)	(97)	(152)
Income tax expense	—	(1)	—	(3)
Net loss	$(93)	$(75)	$(97)	$(155)
Net loss per share:
Basic and diluted	$(1.02)	$(1.04)	$(1.09)	$(2.13)
Shares used to compute net loss per share:
Basic and diluted	91.1	73.2	88.6	73.1

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.